Levetiracetam NDC 51079-821

NDC codes

FDA NDC Directory

Product NDC (as listed)51079-821Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51079-0821Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51079-821-20	51079082120	100 BLISTER PACK in 1 CARTON (51079-821-20) / 1 TABLET, FILM COATED in 1 BLISTER PACK (51079-821-01)Marketed from Nov 4, 2008

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Levetiracetam
Generic name (nonproprietary): levetiracetam
Active ingredients: Levetiracetam — 500 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Mylan Institutional Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076919
Marketing start: Nov 4, 2008
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 51079-821_4369847b-77af-cd07-e063-6394a90a9251SPL ID 4369847b-77af-cd07-e063-6394a90a9251SPL set ID 08e1bfea-7f3f-42d9-823d-f75080e664ffRxCUI 311289UNII 44YRR34555

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451079082120 followed by a unit qualifier and the quantity

Package 51079-0821-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 12, 2025.

Indications (excerpt from the label)

Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) Levetiracetam is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy ( 1.2 ) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy ( 1.3 ) 1.1 Partial-Onset Seizures Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy Levetiracetam is indicated as adjunctive therapy for the treatment of myoclonic seizur…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)